Breast Cancer Clinical Trial

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Summary

This study, ELU- FRα-1, is focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available.

ELU001 is a new chemical entity described as a C'Dot drug conjugate (CDC), consisting of payloads (exatecans) and targeting moieties (folic acid analogs) covalently bound by linkers to the C'Dot particle carrier. ELU001 will be the first drug-conjugate of its kind to be introduced into the clinic, a first in class, and a novel molecular entity.

View Full Description

Full Description

The study has two parts: Part 1 Dose Escalation Safety Study to identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D), and Part 2 Tumor Group Expansion Cohort(s) where specific cancer types will be evaluated for efficacy and safety at the RP2D.

Part 1, subjects with cancer types with a high likelihood of having FRα overexpressing tumors based on historical data, specifically, ovarian, endometrial, colorectal, gastric, gastroesophageal junction, triple negative breast, or non-small cell lung cancers, or cholangiocarcinoma, will be enrolled in a basket clinical study. Retrospective analysis of folate receptor alpha (FRα) expression status will be determined.

Part 2 Stage 1 of a Simon's Two-Stage design, tumor group expansion cohorts, each consisting of subjects with cancer types studied as part of the basket in Part 1.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Patients must meet the following criteria to enroll in this study:

Documented diagnosis of ovarian cancer, endometrial cancer, colorectal cancer, gastric cancer, gastroesophageal junction cancer, triple negative breast cancer, non-small cell lung cancer, or cholangiocarcinoma
No other meaningful life-prolonging therapy option available
Must provide archival tumor tissue or a newly obtained tumor biopsy specimen prior to the first dose of ELU001 for folate receptor alpha (FRα) expression analysis
Adequate organ function
Measurable disease, or in the absence of measurable disease, non-measurable disease as per Response evaluation criteria in solid tumors (RECIST) v1.1
Part 1: Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; Part 2: ECOG performance status of 0 or 1.
Recovered from previous surgeries
Agree to highly effective contraception, not to get pregnant, or for men, not father a child during study participation

Key Exclusion Criteria:

Patients who meet any of the following are not eligible to enroll in this study:

Active or ongoing eye disorders
Taken any treatments that use the protein folate receptor alpha or FRα to work
Taken any other experimental treatments
History of significant cardiac issues or other cancers within 3 years.
Significant anemia, significant neutropenia, or significant thrombocytopenia (e.g., not enough platelets in your blood - platelets held stop bleeding in your body)
Detectable viral load for HIV (human immunodeficiency virus), hepatitis B or C.
If you are pregnant.
Part 1: Cannot have active autoimmune diseases such as rheumatoid arthritis, SLE (systemic lupus erythematosus), ulcerative colitis, Crohn's Disease, MS (multiple sclerosis), ankylosing spondylitis, thyroiditis that require treatments that suppress your immune system.
Part 1: if your cancer has spread to your brain.
Part 2: You can have cancer that has spread to your brain but there are exceptions. The cancer in your brain cannot be causing any symptoms, it cannot be larger than 3 cm, there can be no evidence on a scan that shows your brain tissue has shifted from its expected position inside the skull (called "herniation") or be bleeding in the skull or brain itself (called "hemorrhage").

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

166

Study ID:

NCT05001282

Recruitment Status:

Recruiting

Sponsor:

Elucida Oncology

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Mayo Clinic - Phoenix, AZ
Phoenix Arizona, 85054, United States More Info
Tanios Bekaii-Saab, MD
Principal Investigator
Vinicius Ernani, MD
Sub-Investigator
Sara Luster, PA
Sub-Investigator
Cassandra Moore, MD
Sub-Investigator
Renee Cedillos, PA-C
Sub-Investigator
Kelley Rone, RN, NP
Sub-Investigator
Mahesh Seetharam, MD
Sub-Investigator
Parminder Singh, MD
Sub-Investigator
Mohamad Sonbol, MD
Sub-Investigator
Mayo Clinic - Jacksonville, FL
Jacksonville Florida, 32224, United States More Info
Yujie Zhao, MD, PhD
Principal Investigator
Steven Attia, DO
Sub-Investigator
Saranya Chumsri, MD
Sub-Investigator
Gerardo Colon-Otero, MD
Sub-Investigator
Jeremy C Jones, MD
Sub-Investigator
Yanyan Lou, MD
Sub-Investigator
Rami Manochakian, MD
Sub-Investigator
Kabir Mody, MD
Sub-Investigator
Jason Starr, MD
Sub-Investigator
Winston W Tan, MD
Sub-Investigator
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando Florida, 32827, United States More Info
Osheka M Hansel, APRN
Contact
Cesar A Perez Batista, MD
Principal Investigator
Michel Valez, MD
Sub-Investigator
Ernesto B Linares, MD
Sub-Investigator
Osheka M Hansel, APRN
Sub-Investigator
Mayo Clinic - Rochester, MN
Rochester Minnesota, 55905, United States More Info
Wen Wee Ma, MBBS
Principal Investigator
Alex Adjei, MD, PhD
Sub-Investigator
Thorvardur Halfdanarson, MD
Sub-Investigator
Thanh P Ho, MD
Sub-Investigator
Joleen M Hubbard, MD
Sub-Investigator
Zhaohui Jin, MD
Sub-Investigator
Sani H Kizilbash, MD, MPH
Sub-Investigator
Roberto A Leon Ferre, MD
Sub-Investigator
Konstantinos Leventakos, MD
Sub-Investigator
Minetta C Liu, MD
Sub-Investigator
Amit Mahipal, BS
Sub-Investigator
Aaron S Mansfield, MD
Sub-Investigator
Ciara O'Sullivan, MB, B.Ch
Sub-Investigator
Andrea E Wahner Hendrickson, MD
Sub-Investigator
Mojun Zhu, MD
Sub-Investigator
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Clinical Trials Information
Contact
646-888-4226
Yonina R Murciano-Goroff, MD, MsC
Principal Investigator
Alexander Drilon, MD
Sub-Investigator
Allison Betof Warner, MD, PhD
Sub-Investigator
Michelle Bradbury, MD, PhD
Sub-Investigator
Yolanda C.D. Bryce, MD
Sub-Investigator
Margaret Callahan, MD, PhD
Sub-Investigator
Claire Friedman, MD
Sub-Investigator
James Harding, MD
Sub-Investigator
Komal Jhaveri, MD
Sub-Investigator
Christopher Klebanoff, MD
Sub-Investigator
Chrisann Kyi, MD
Sub-Investigator
Bob Li, MD
Sub-Investigator
Ezra Y Rosen, MD, PhD
Sub-Investigator
Alison Schram, MD
Sub-Investigator
Soo Ruym Yang, MD
Sub-Investigator
Robert Young, MD
Sub-Investigator
Dmitriy Zamarin, MD, PhD
Sub-Investigator
Duke University Medical Center - Duke Cancer Institute
Durham North Carolina, 27719, United States More Info
To be Determined
Contact
Carey Anders, MD
Principal Investigator
James Abbruzzese, MD
Sub-Investigator
Gerard Blobe, MD PhD
Sub-Investigator
Niharika Mettu, MD PhD
Sub-Investigator
John Stricker, MD
Sub-Investigator
David Hsu, MD PhD
Sub-Investigator
Michael Morse, MD
Sub-Investigator
Hope Uronis, MD
Sub-Investigator
Nicholas Devito, MD
Sub-Investigator
Evan Dropkin, PA
Sub-Investigator
Carolyn Tashie, PA
Sub-Investigator
Margo O'Neill, PA
Sub-Investigator
Deanna Griffie, NP
Sub-Investigator
Paula Kennedy-Newton, NP
Sub-Investigator
Gretchen Kimmick, MD
Sub-Investigator
Kelly Westbrook, MD
Sub-Investigator
Jeremy Force, MD
Sub-Investigator
Rita Deimler, NP
Sub-Investigator
Rachel Pienknagura, PA
Sub-Investigator
Rebecca Previs, MD
Sub-Investigator
Sarah Collins, NP
Sub-Investigator
Kimberly Nolte, PA
Sub-Investigator
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia Pennsylvania, 19107, United States More Info
Babar Bashir, MD
Contact
Babir Bashir, MD
Principal Investigator
Maysa Abu-Khalaf, MD
Sub-Investigator
Rita S Axelrod, MD
Sub-Investigator
Jennifer M Johnson, DO, PhD
Sub-Investigator
William K Kelly, DO
Sub-Investigator
Daniel Lin, MD
Sub-Investigator
Neil D Palmisiano, MD
Sub-Investigator
James A Posey, MD
Sub-Investigator
Russell J Schilder, MD
Sub-Investigator
William J Tester, MD
Sub-Investigator
Eleanor L Vanderklok, CRNP
Sub-Investigator
Cynthia Wheeler, CRNP
Sub-Investigator
Sarah Cannon Research Institute at Tennessee Oncology
Nashville Tennessee, 37203, United States More Info
Erika P Hamilton, MD
Principal Investigator
Todd M Bauer, MD
Sub-Investigator
Howard A Burriss, MD
Sub-Investigator
Benjamin Garmezy, MD
Sub-Investigator
Melissa L Johnson, MD
Sub-Investigator
Meredith McKean, MD
Sub-Investigator
Meredith S Pelster, MD
Sub-Investigator
David R Spigel, MD
Sub-Investigator
Mary Crowley Cancer Research
Dallas Texas, 75230, United States More Info
Karina Amaro, Study Coord
Contact
[email protected]
Teresa Marquez, ClinTrialMg
Contact
[email protected]
Douglas Orr, MD
Principal Investigator
Jairo R Olivares, MD
Sub-Investigator
Reva E Schneider, MD
Sub-Investigator
Minal Barve, MD
Sub-Investigator
New Experimental Therapeutics of San Antonio (NEXT Oncology)
San Antonio Texas, 78229, United States More Info
NEXT Coordinators
Contact
210-580-9500
[email protected]
Anthony W Tolcher, MD, FRCPC
Principal Investigator
David Sommerhalder, MD
Sub-Investigator
Sridhar Beeram, MD
Sub-Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

166

Study ID:

NCT05001282

Recruitment Status:

Recruiting

Sponsor:


Elucida Oncology

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.